Drug intelligence / Profile preview

MH-04

Development stage: Unknown
Lead developer: Affiliated Suzhou Hospital of Nanjing Medical University

Overview

MH-04: sourced facts only. name: "The ALOX12-targeted compound MH-04 was identified via virtual screening, with an IC₅₀ value of 0.72 μM." [PMID:42430827]; target: "The ALOX12-targeted compound MH-04 was identified via virtual screening, with an IC₅₀ value of 0.72 μM." [PMID:42430827]; developer: "Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215001, PR China." [PMID:42430827]

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)

Beyond the preview

Go deeper on MH-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MH-04.